Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
ENTA Weekly Chart

Old Forum Content for ENTA

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • thehook1: $ENTA nice move on upgr...low risk for me
  • spmeyers: $ENTA looks like it wants to break out
  • TRICIA: $GILD - why the jump? simple .. the HEPC competion from $ABBV and $ENTA's offering got FDA public safety warnings .. the sell panic has destroyed $ENTA now down 50% and $ABBV down 11% .. *(enta's pipeline was limited) - HEPC remains GILD's .. the E/R for GILD is Tues AH
  • gwenzee: @TRICIA $GILD $ABBV $ENTA $ESRX Noticed that ESRX went down today. This was the company of bean counters who chose $$ over patients. Also, some seeking high office have declared a war on drug pricing. Perhaps they should review recent outcomes? IMO drug pricing should not be used as a political football. Comments resulted on IBB taken to the woodshed. Perhaps results will send the sector higher. Hope springs eternal.
  • jwstich: @TRICIA $GILD $ABBV $ENTA Adam Feuerstein at The Street has written an article essentially saying that the selling in $ABBV is overdone. I don't have a link, but the article is worth reading.
  • captron: $ENTA - Stopped out. Nice profit. Thanks Tricia. Will wait to reload.
  • Prazan:
  • captron: @Prazan $ENTA- I am playing this as a short squeeze. There is about 13 days of covering on the books.
  • pcotton: #scan - not to change the subject, but here's the #bottomsUP results: $AA $ARII $CLD $CSLT $CSOD $DAR $ENTA $HPQ $IRET $JOY $NRG $OCN $PPC $SCHN $SPPI $SRPT $TIF
  • pcotton: #scan #bottomUP commentary on some prior results I'm watching, may buy or buy back:
    $ANDE - phase 3 bounce off 50, decent followup candle
    $ARII - big earnings beat spike, mild pullback showing support
    $BNCL - earning beat spike, pullback and uptrend, ...
  • Prazan: @luongobill12 @Aragorn Here's the list of BUG & FlU tickers @Tricia initiated in the forum several weeks ago, with a few changes: $IBIO,$TKMR,$CEMP,$AKAO,$ACT,$CBST,$NBY,$MDCO,$BCRX,$TTPH,$NVAX,$SNY,$DRTX,$HEB,$ENTA,$DVAX Note that his list includes companies in the antibiotics field, $CEMP notable among them.
  • pcotton: ...
    $CAT $CRS $ENTA $FCX $FLR $MDU $NAV $NTLS $UTEK $VCRA $VHC
    CAT - 20 crossing over 50, consolidating
    CRS - 20 near crossing over 50, longer base than the failed rally of late 2014, when the 20 didn't come near the 50. Alert over prior high 43.64
    ENT ...
  • TRICIA: @dunsek $ABBV -- I played a wee bit of $ENTA all week as well - claims of 8 week HEP C cures and ENTA gets a much higher payment from ABBV for the new compound ... on the other hand ... GILD will have a 6 week cure by then ... ( that's the talk ... earnings and conference calls will be interesting...
  • moneyHoHo: @moneyHoHo Well, $ENTA is working.
  • moneyHoHo: $ENTA see that pattern last 2 days. Buy a break above Friday's candle. Add over 36.60. Look for a slow drift up to 50% fib retracement $42ish?
  • woodman: $ENTA - getting interesting down here near-ish the 200 day. Its and $ABBV's V-Pak sales won't touch $GILD's, the drug has a place in the market. $ENTA is cashing royalty checks and I wonder if that will be showing up in its earnings next month (specific date unknown).
  • TRICIA: HARVONI/Sovaldi selected as Exclusive HCV drug by 2 more Humana and Pilgrim. $GILD $ABBV $ENTA courtesy of @MarkSchoenebaum
  • TRICIA: $ENTA ---As suspected .. $ABBV 's goal is to go alone .... $ENTA ABT-493 nextgen PI/NS5A for HCV, PIIb data maybe at #AASLD but by end of year; once-daily pangenotypic regimen is goal #JPM15 $ABBV (listen to Webcast)
  • jmat2413: $ENTA heating up in the last few minutes.
  • TRICIA: $GILD - $ABBV,$ENTA - after I confirmed my sales estimates with some analyst buddies(both buy and sell side) - this SA article got posted http://seekingalpha.com/article/2801485-assessing-gileads-reality-perception-gap-upside-revenue-surprise _ READ it ... better yet study it ... these scrip counts don't lie AND the Pricing here is accurate. I bought back GILD around $88 bfore XMAS AND please note it closed ↑ 1.5% today with IBB down same ... Add to that, they bought a "NASH" pvt company today ... JMP Conference will tell will be about NASH (yes I think it is ridiculous but the market doesn't) Long $GILD - my second long term hold for 2015...I expect earnings to be another blowout .. thinking the market does too
  • scottto: $ENTA - Rolled Jan 40 calls. Originally BTO $6.75, STC $12 and BTO Apr 45 calls for $10. Have more time for $ABBV drug to hit their bottom line. Pocketed some profits.
  • woodman: $GILD, $ABBV $ENTA $ESRX - Pharmacy Benefit Manager $ESRX had been railing against $GILD's pricing for a long time now. It has been perhaps the most vocal of the bunch. That it struck an exclusive deal with $ABBV to place its drug on the formulary ...
  • woodman: $ENTA - well, there it goes. I bought on the post-gap-up dip this morning. Would have been that I held it last week, but that's rearview mirror now. So, I bought back this morning.
  • woodman: @AnderronTrader $GILD $ABBV $ENTA - as I have said, I believe ENTA, with a market cap under $1 billion and sweet royalty $$ from ABBV sales coming its way, will be the big winner here. That's what I bought -- actually, bought back -- this morning.
  • AnderronTrader: @woodman missed your post on $ENTA. Thanks for bringing that up.
  • TRICIA: $GILD $ENTA $ABBV -- ESRX has had it's Waxman day ... watch over next 2 weeks as ESRX horror stories emerge. (The self appointed Robin Hood CEO of ESRX booked 25M in salary last year while paying members had to put together life savings to hire attor ...
  • scottto: $ENTA - Quick math - They have approx 20 million shares outstanding. They are due 25% royalties of $ABBV's cocktail sales (since their component is 1/4th of the cocktail, i believe). At $80K per treatment. $ENTA should receive $20K of that. For every 1000 scripts that are filled, $ENTA will receive $20M or about $1 per share in earnings. Nice juice..... Eventually $ABBV may realize that they are giving up too much and need to take over $ENTA.....
  • woodman: @scottto $ENTA - this is essentially what I have been pounding the table on, but in a slightly different manner. ENTA's market cap is about $850 million. $ABBV's is about $107 billion. Orders of magnitude. I think ENTA's royalties are larger than ...
  • woodman: @Aragorn, et al. $ABBV/$ENTA - I still think you're all looking at the wrong one here. I'm interested in $ENTA on a pullback, not $ABBV. I sold $ENTA yesterday b/c I didn't want to hold through approval (which pretty clearly seemed already baked in ...
  • TRICIA: $GILD --- $ABBV, $ENTA .... WSJ article this am ... I am still not buying it .. priority review due Monday ... seems to not be a priority ... hmmm - see twitter for all my cons .. glta if you are long .. but $ I don't think the margin is there for $ABBV so discounts to Solvadi and Harvoni may not happen or be a big deal ..
  • woodman: $ENTA - coming PDUFA. It's trying to fight itself out of the corner.
  • TRICIA: $GILD -- $ABBV $ENTA --(no position in either) PDUFA prioroty review Mon 12/22
    1) Market doesn't give a rats ass about ABB/ENTA ... here is why

    1- Compliance issue - $ABBV 6 Pill regeime versus 1 - ( "Real life" adherence in HIV was 50- ...
  • TRICIA: $ABBV $ENTA - #HEPC PDUFA coming up in 6 days ...approval likely, price advantage maybe not ... mkt not buying up as expected? hmmm BTW $ABBV downgraded
  • TRICIA: $ABBV vs $GILD ... $ABBV Can't be that aggressive ... until they buy $ENTA ... must pay 30 - 45% to $ENTA ... see all my prior notes ... Recall the reaction to France's demand for Solvadi pricing ... that had to shake up the market plan in $ABBV I just booked profits in both and will step aside to see what happens next Monday
  • scottto: @TRICIA - $ENTA to me is the trade. Small company looking at either take out or major increase in EPS (like possibly $5-10 per share earnings, put that with the conservative 14 multiplier for pharma and you get some nice price action). Long $ENTA 40 calls multiple expirations in 2015
  • RedLeaf1: @TRICIA $ABBV $GILD $ENTA $SSH Yes, thanks for your thoughts. $SSH goes down everyday. Any opinions on $SSH?
  • TRICIA: $ABBV/ $ENTA -- @Scotto ---
    Mon cher Scotto - comment était votre voyage ? Je espère que le glamour de Paris n'a pas obscurci votre jugement ..
    Je ai pensé que le commerce était $ ENTA aussi ... et 10,00 Iam jusqu'à ...
  • scottto: @TRICIA - $ENTA - Oui, notre voyage a été merveilleux . La nourriture , en général, est à mourir . Avec vos profits de $BLUE vous devriez vous offrir une semaine à Paris ! Merci pour l' aperçu $ENTA . Je irai contre mon propre péril . Pour votre santé , -M. Scotto For Lou and Mr Adams - Broaden your horizons, copy and paste into Google translate....
  • woodman: @TRICIA $ABBV $ENTA - Since your posts in English are quite confusing, writing in a foreign language can only help. :-0
  • RedLeaf1: @Diana2010 @Tricia Adding my Happy Thanksgiving wishes and thanks to @Tricia for sharing ideas on $ENTA $ABBV $SSH $RDNT. also thanks to @scotto for comments on the same.
  • TRICIA: $BMY @momeyhoho ... #HEPC recieved a CRL for datclatasvir - $BMY Not just a complete response letter - "FDA declines to approve Bristol-Myers hepatitis drug" - http://yhoo.it/1ATMFNA $GILD, $ABBV/$ENTA
  • TRICIA: $ABBV/$ENTA --- no one knows the price of treatment and you won't until Dec22 -..people can ONLY guess There are two combinations ... the 3 pill combo - Enata will receive 30% on worldwide sales ...ABBV gets 70% the 2 pill combo - Enata will receive 45% of worldwide sales .. $ABBV get 55% $GILD - receives 100% for Sovaldi ...and for Harvoni - Ask yourself .... Can $ABBV induce with a discount???? I have a 1/2 position in $ABBV -- willride it up with the crowd into PDUFA I have a full position in $ENATA ... same as above $BMY's news this morning shows how very difficult and expensive it is to bring a Cure to market... Long GILD in long term accounts ...
  • RedLeaf1: $ABBV $ENTA For those following this trade, Enanta Pharmaceuticals Inc (ENTA) is expected to announce 1st quarter 2015 results on or around February 16, 2015.
  • woodman: $ENTA decent drop today back to rising support. I would have added today, but I'm long enough this one. I think it will end up being a buying opportunity.
  • jmat2413: @woodman $ENTA coming back strongly. Now above lower BB and the 50 dma
  • woodman: @jmat2413 $ENTA - well the drop didn't last very long. I believe Tricia is still a fan of this one. She's been on it for a long time.
  • TRICIA: #HEP C $ENTA... $ABBV ... jeepers $ENTA swings from a whopping 10% .. now 44.2 was 40.30 at 9:30 I wrote this much earlier in another room - $ENTA .. possible explanation for this continued inverse performance to $ABBV is 1. The mkt does not' understand the relationship with $ABBV 2. The market doesn't get that $GILD has a 20% price advantage t $ABBV ( never mind that $GILD is first to market and has a single pill Harvoni combo.... 3. $ABBV is going to acquire $ACHN instead ... 4. $ENTA is so thinly traded, that manipulating the prices is very easy... All still apply ... I am long $ENTA and have been ... failed to add this morning ..also have $ABBV .. PDUFA priority review for HCV genotype1 is Dec 21... could come early...
  • RedLeaf1: @TRICIA $ENTA $ABBV I have held $ABBV since the split from $ABT, and added $ENTA along with you.
  • jmat2413: $ENTA Exceeds yesterday's high - possible bullish engulfing if it stay up here. Also did not add today.
  • scottto: @TRICIA - Good memory! Leaving for Paris on Friday afternoon. Looking forward to the $PATE Unfortunately, $GILD is making pate out of me right now. But things will change before 2016.... I'm patient. Meanwhile I also own $ABBV and $ENTA (would love to see $GILD buy that one just to stick it to $ABBV but Feds probably wouldn't let it happen). A votre santé,
  • scottto: @moneyHoHo - As @TRICIA and I posted about the other day, $ENTA may be the best way to play the $ABBV HepC trade. They get 20% royalty being the developer of one of the 3 components of the $ABBV cocktail. $ENTA is a 20 million share company vs $ABBV 1.5 billion shares. Where will $100 million in earnings help the most? At the very least, for $800M, $ABBV should buy them, a bargain at 2x the price long term....
  • RedLeaf1: @moneyHoHo $ABBV $ENTA Thanks to everyone on this Post and @TRICIA for these ideas. I will join $ABBV a bit lower and also add $ENTA. I am already in $SSH per @TRICIA. Good luck all.
  • woodman: $ENTA bounce at 50 day after pullback. $INO creeping up.
  • woodman: $ENTA - anyone grab any? Mentioned it this morning off the 50 day.
  • TRICIA:
  • TRICIA: #AASLID2014 - IT's all about LIVER ..(hideous childhood memory - Mom making LIVER and Onions omg -- gag me :-( Nov. 7-11: American Association for the Study of Liver Disease (AASLD): #NASH $GILD, $CNAT, $ICPT, $GALT, $GLMD, $ALGFT $ALNY,$MDCO $ACHN #HEPC $GILD, $$BMY, $MRK, $ABBV, $ENTA, $RGLS, .. $ACHN no show> re it's NUC? #HEPB $ARWR, $TKMR, $ALNY, $CELG $GILD, $GBIM, $TLOG Looking at these companies, & considering the money being poured into all these very very expensive trials --I'm thinking this is a make or break weekend May we need a LIVER ETF - Call it $GAG (from the Mommy dearest chronicles) Feuerstein posed these questions .. http://adamfeuerstein.tumblr.com/post/101757154622/five-burning-questions-liver-disease-stocks FD - Long GILD, ENTA, TKMR, CNAT, GBIM - I will be in Boston this weekend as a guest of some bio - analysts ...excited to meet them and maybe look for a job.
  • scottto: @TRICIA - $ENTA $ABBV - Looking at just the stock fundamentals, if it's true that 20% of Hepatrix (my made up name for $ABBV treatment) revenues will be paid to $ENTA, then I think $ENTA is the buy. With outstanding shares of about 20 million for $ENTA and 1.5 billion for $ABBV and let's just pencil a conservative $2 billion in Hepatrix revenue. For $ABBV, this would give about $1.6 B bump to revenue or about $1 EPS, good for say $15-20 in PE multiple For $ENTA, this would give $400 M revenue or $20 per share. Pretty significant to say the least. Plus they have other protease inhibitors out with other companies.... Worth a shot.
  • TRICIA: @scottto - that is ewhy I am and have been long $ENTA .. of the two-- better r/r inho.
  • TRICIA: $ABBV/$ENTA - HEPC - ABBV has a near 2B expense walking from the Shire deal ..ENTA provides the critical component to ABBV's answer to HEP C Genotype 1, or 70% of the HEPC population - there are a few questions about the data harvest but that can wa ...
  • TRICIA: #HEPC $ABBV /$ENTA - $MRK - $ACHN ...$GILD -@Scotto, @bradleyrich - there are so many things going in Liver tickers ... I hold GILD, and ENTA - next week is ASSLID - so add NASH, HEP B and then HEP C ...so I see 16 tickers to watch, consider or buy going into next weekend... I can't or won't own them all ... I don't see a reason not to buy ABBV - but I don't see any reason to but at the expense of my other liver holdings ... I hope that helps...
  • moneyHoHo: @scottto Check out $ENTA
  • woodman: $ENTA - added a little this morning following my entry under $42 on yesterday's puking.
  • moneyHoHo: $ENTA taken to the woodshed and beaten mercilessly. Is it really dead tho? Data in December.
  • moneyHoHo: $ENTA could pop next week.
  • RON: Stocks above the 200MA with Accumulation out of 1,000 stocks and ETFs A very simple stock up trend of a few MA’s in harmony model with accumulation - sorted by relationship to the 50MA, a @Tricia favorite $CENX furthest away by 45%. CENX CSIQ AEO ARWR AMBA RKUS ANAC STLD AMX NEO AMGN KMP BG SAVE THC CTL STRZA DECK GIII DJUSST ISRG CAR HRL WMC MENT WYN NRF MSFT ENTA LEG KMI LVLT WY CTAS LTC BBRY NMFC IGF APC IGT TGTX $CENX $CSIQ $AEO $ARWR $AMBA $RKUS $ANAC $STLD $AMX $NEO $AMGN $KMP $BG $SAVE $THC $CTL $STRZA $DECK $GIII $DJUSST $ISRG $CAR $HRL $WMC $MENT $WYN $NRF $MSFT $ENTA $LEG $KMI $LVLT $WY $CTAS $LTC $BBRY $NMFC $IGF $APC $IGT $TGTX If using these as potential tradable watch list, apply all of @DANS teaching methods.
  • scottto: @nmshore - $GILD - Competition by year-end. There's one HepC-related PDUFA and that's slated for 12/21/14. The $ENTA $ABBV combination. http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=1939816 I think a deliverable market competitor by year-end is way optimistic....
  • moneyHoHo: $ENTA Mentioned this the other day.
  • msb: @moneyHoHo $ENTA - thanks! I bought it when you mentioned it.
  • moneyHoHo: $ENTA - IBB has been rockin' but this one is still in a tight consolidation. I like the weekly.
  • Tricia: $ENTA: ↑6% , partner with ABBV Hep C play -- long . Enanta Pharma biotech development of small molecule drugs for ID infectious disease Pipeline : ABT-450, a protease inhibitor that is in Phase III (HCV); ABT-493, a next-generation protease inhibitor for HCV ; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, preclinical stage HCV Nucleotide Polymerase inhibitor program for HCV. Bicyclolide antibiotic comprising EDP-788 for MRSA methicillin-resistant Staphylococcus aureus bacteria. COLLABORATIONS and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. founded in 1995 and is headquartered in Watertown, Mass
  • Tricia: $NPSP FBR Capital Starts NPS Pharmaceuticals Inc. $NPSP at Outperform http://streetinsider.com/r/9757610 (AsComm Sept 12, Pdufa Oct 24 - http://finance.yahoo.com/news/nps-pharma-reports-second-quarter-203000224.html $ENTA FBR Capital Starts Enanta Pharmaceuticals $ENTA at Outperform http://streetinsider.com/r/9757633 8/13 Zacks upgraded $enta today from neutral to outperform with a $47.10 PT. PDUFA - DEC 21 - Prioroty Review HCV Combo with Abbv http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=1939816 FD: Long 1/2 position ENTA, and 1/3 position $NPSP - adding here
  • Tricia: #BIOTECH EArnings week - 44 This Week! EArnings Mon 08/11 incl: $MACK $INO $AKBA $BLUE $RYLP $ENTA $PBYI $HALO (26 Today) Earnings Tues 08/12 incl: $INSY $BCRX $ARRY $RNA $PETX $STEM $ARWR (13) Earnings Wed 08/13 incl: $EPZM $CNAT $ONTX $TKMR There is a lot of data this week also .. should be very interesting $EPZM data at ASH Lymphoma meeting on August 12 $OPK will have top-line Rayaldee data on Monday night as well. Hep B Updates from $ARWR, $TKMR -- $ALNY will have another roundtable with $MDCO
  • Tricia: $GILD: Marching to $140.... Next 2 PDUFAs are for the HIV franchise -- Can the US Gov't and or the Insurers change the pricing ...NOPE repeat NOPE What will change the pricing? "competition" $ABBV/$ENTA and then $MRK Wanna know how powerful and focused the company is ... they too are working on HBV .... surprise ...lol
  • woodman: $ENTA - mentioned it yesterday as offering a chance to get in as it was on a couple of differently drawn support levels. Phase 3 today?
  • woodman: $ENTA - looks like it is giving an opportunity. It broke pretty well up and out of its channel, pulled back, and is bouncing at what had been the channel resistance (channel top). Now new support? Also looking at the 3/21 high as prior horizonal resistance now possibly support. Gets you to the same place, roughly.
  • SeaKingA: $ENTA @woodman, any calendar dates of which to be wary?
  • woodman: @SeaKingA $ENTA - I'm aware only of end of year: http://www.biopharmcatalyst.com/fda-calendar/ They got a downgrade by Baird on basis of its "fair valuation" but they remain a vialble takeout candidate by ABBV.
  • SeaKingA: $ENTA @woodman Thanks for reminder re: buyout candidacy.
  • Tricia: $ABBV $SHPG AbbVie confirming it made an approach, per statement. $46.5B offer in cash and stock. And falls under UK takeover rules - Under UK takeover code, $ABBV has until July 18 to announce firm intention to make an offer for Shire or walk away.... it appears $SPHG declined .. but the story is not played out ... @ Sierra Jim .. no, I would not buy ABBV .. I own and keep adding $ENTA ...
  • woodman: @Tricia What is taking $ABBV so long to buy $ENTA? :)
  • Tricia: @woodman $ABBV/ $ENTA - distractions (SHIRE)and ... FDA approval ..
  • woodman: $ENTA - still going, Tricia. :)
  • Tricia: HEPC - $ENTA - ($ABBV will buy this)...up 25% since early April - I still hold my core positions in GILD in my Retiementand in my niece's college funds. The market doesn't understand HEPC, the genotypes, the combo's, the pricing, the treatment protocols,and the clinicians view. I have been moving GILD money into ENTA for a while with no regret. Like Steve Weiss I won't fight it right now ... but my core position (gains over 350%)- My calendar is marked for trial announcements in SEPT and the Liver Conf in Nov. I promise you ... GILEAD will wipe HEP C off the face of the earth long before Merck can spell SVR.. The forum has plenty of my posts on ENTA .. hope you all bought some ... even yesterday
  • woodman: @Tricia $ENTA - been long. Thx as always Tricia.
  • Tricia: $ENTA $ABBV Oral Treatment for Hepatitis C Under Accelerated Assessment by European Medicines Agency ABBV I still think the trade is $ENTA
  • woodman: $ENTA was in a nice buy spot on Friday. Also like $MNTA and $INTM.
  • Tricia: $GILD - selling my ACHN here ... happy with 2 day scalp from pr ysterday .. $ENTA - I added yesterday .. THIS IS THE BUYOUT for ABBV and the next real potential HCV competition for GILEAD ...been pounding the table on this ( or was I inside some coffin pounding the roof under the "biotech is dead") Next time there is a fall in the IBB (and there will be a next time), step away and hunt for buys based on the technology .. not the charts ...it is so hard to do but that is the way to do it ... - contrary to the experts, ACHN & MERCK are a lot more than 2 or 3 years away --
  • snmtraders: @Tricia $GILD $ENTA So glad you were able to pop that lid off the coffin, Tricia. Thanks for all your shared biotech knowledge!
  • mradams0621: @Tricia $CLDX $GILD $ENTA My plan- take profit on CLDX $16 calls around 17 or 18, wait for a retest of the 50ema to reload and double down on long term stock position to lower cost basis. Bullish based on you, and others in the forum believing in this one longer term, as I just do not understand the language well enough to do my own research, but I keep trying. Until then, I sure appreciate your input. I am confused by your prior post on ENTA and GILD. If ENTA will be the new competition for GILD, would you suggest selling GILD to buy more ENTA? Or do you remain bullish on both? Thanks so much Tricia, you are the best. MikeMikeMike
  • woodman: $ENTA one the few biotechs I own right now is breaking out of a symmetrical triangle.
  • woodman: @chuckd bought some $BCRX and $NVAX today. $ENTA nice breakout today. $ITMN looks like it wants to move higher.
  • woodman: $ENTA - Keep watch for a move out of a symmetrical triangle at the 50 day.
  • Tricia: ...
    the trial status of $ENTA/$ABBV (1st or 2nd QTR 2015, and $MRK (late 2016 at the earliest)?
    - the stock is CHEAP CHEAP even at 85$
    - this is a CURE ... let me say it again ... This is a CURE & several trials are now pointing a single pill can ...
  • Tricia: ...
    I continue to see ENTA/ABBV as potential competitors, but it still 9 months from now at the earliest ... BTW - if you have to choose and I do because I don't want to many Bio's in my portfolio - the correct choice is $ENTA .... ABBV will have to bu ...
  • Tricia: Off Topic: Over the weekend I decided to take a vacation for next few weeks and so did several members of my family ...we are heading to OBX - (Ginny, will call you but no stock talk! lol) ... after I missed the XMAS/New Years holidays, we all decided time goes too fast, and rented a few houses for 2 weeks! Take care all --trade carefully and trust your studies and work - contrary to their opinions, no one here is any smarter, even if they think so .. it is your money. Hope you all enjoy family time and welcome the spring we have earned!. See you in 2 weeks - remain long in $GILD, $ENTA,$MDTR,$FB,$APC,$WILL,$LLY, - with small starter and/or placeholder postions in $ICPT,$JAZZ, $ARIA,$MDSO, $CERN, $OHRP, $MDWD - remain at 50% cash ...take care ... xxxoooxxx
  • Tricia: $GILD @bradleyrich & Aragorn GILD: $MRK announced phase II results from 44 patients ... and the reported reseults are incomplete - that means MRK is 3 years behind GILD. $BMY also announced but I think there is an issue of Genotype 1A or 1B .. ...
  • Tricia: Hepatitis ... Hep $C - the potential market continues to rise .... up to $9B now ...... that is why $MRK, $BMY and ABBV/ENTA are chasing GILD. BTW ... SCRIP COUNT for SOLVALDI is negative......yes, negative .... means the supply ran out ... the demand is so high they can't keep up .... I added yesterday and more today ... I hold $GILD overweight .. will sell some back as the stock gets back to 80 .. want a full position for EASL next week and ASCO in 5 weeks - I hold ENTA( this is the nuc holder in the ABBV/ENTA collaboration .. have it on tight leash .. not sure why it's off today ... EASL should be very big for $ENTA $MRK, BMY.... sorta a yawn for HEPC but they will be making noise next week see next note fro $HEP B ......
  • Tricia: Good morning fellow SMMer's ...today I am watching the results for $DRTX and $CBST AdComm's because I am interested in the battle against drug resistant bugs... Also watching $TKMR ... the ebola virus ( zaire strain ) has now claimed 80 lives and depending on what source is either contained OR NOT... we are bombarded with facts about plane that disappeared and disinterested in a virus that Putin/No Korea can micronize - not saying the plane isn't important just frustrated with the lack accurate news .... Waiting for Abstracts for EASL .... hepatitis isn't over ( neither is GILD) but I am interested in the trial data fro ABBV/ENTA - eapsecally $ENTA ... and of coutrse $MRK Also watching CLINT, PIEX and $TSLA - after 60 minutes
  • Tricia: ...
    the European Liver Conference is April 9th .... so if you hold $ABBV, $MRK,BMY,$ENTA, and no $GILD you may make some money ...... I will make money because I hold $GILD and $ENTA ( as previously satead here.... this is the one to hold of the ABBV/E ...
  • Tricia: GILD: @Steve71 .... I agree with you ASCO thesis .... I will give you a much bigger catalyst ... EASL2014 ... Liver conference in Europe April 9 - 13th ... $HEP C all over it ... $GILD is the star but you have to watch the up and comers The Players ... $ABBV & $ENTA .... I am long $ENTA .... $BMY :have 1/3 left which is very green today MRK: I have a 1/4 position also green
Visit the Trading Forum to join in the discussion.
Stock Price $17.11
Change 3.51%
Volume 57,805

Enanta Pharmaceuticals Inc is a research and development focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.

Request Video of ENTA
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!